论文部分内容阅读
目的:研究苦桉祛疹凝胶对大鼠湿疹模型的影响并探讨其作用机制。方法:40只SD大鼠采用二硝基氯苯制作湿疹模型,分为湿疹模型组,苦桉祛疹凝胶组(涂苦桉祛疹凝胶250 mg),阳性药组(涂冰黄肤乐软膏250 mg),另设正常组。通过皮损评分评价疗效,石蜡切片苏木素-伊红(HE)染色观察病理改变,酶联免疫吸附测定(ELISA)法检测血清γ-干扰素(IFN-γ),白细胞介素-4(IL-4),白细胞介素-17(IL-17),白细胞介素-31(IL-31),白三烯B4(LTB4),白三烯C4(LTC4)水平,免疫组化法和蛋白免疫印迹(Western blot)法检测皮肤半胱氨酰白三烯受体1(Cys LTR1),半胱氨酰白三烯受体2(Cys LTR2)蛋白的表达。结果:与正常组比较,湿疹模型组病理改变呈角化过度、角化不全、颗粒层肥厚、棘层肥厚,IL-4,IL-17,IL-31,LTB4和LTC4升高(P<0.05),Cys LTR1和Cys LTR2蛋白表达上调。与湿疹模型组比较,苦桉祛疹凝胶组皮损评分于用药6 d后下降,病理改变减轻,IL-4,IL-17,IL-31和LTC4水平下降(P<0.05),Cys LTR1和Cys LTR2蛋白表达下调,而LTB4水平无统计学差异。结论:苦桉祛疹凝胶对大鼠湿疹模型有治疗作用,与下调血清中IL-4,IL-17,IL-31和LTC4水平以及皮肤Cys LTR1和Cys LTR2蛋白的表达有关。
Objective: To study the effect of Eucalyptus Rubra gel on rat eczema model and to explore its mechanism. Methods: Forty SD rats were treated with dinitrochlorobenzene to make the model of eczema. The models were divided into three groups: eczema model group, Eucalyptus Edema gel group (Eucalyptus Eucalyptus Rubra gel 250 mg), positive group 250 mg), another set of normal group. The curative effect was evaluated by the skin lesion score. The pathological changes were observed by hematoxylin-eosin (HE) staining and the levels of IFN-γ, IL- 4, IL-17, IL-31, LTB4, LTC4, immunohistochemistry and Western blot Western blot was used to detect the expression of Cys LTR1 and Cys LTR2. Results: Compared with the normal group, the pathological changes in the eczema model group were hyperkeratosis, keratosis, granular layer thickening, acanthosis, IL-4, IL-17, IL-31, LTB4 and LTC4 ), Cys LTR1 and Cys LTR2 protein expression is up-regulated. Compared with the eczema model group, the scores of lesions in the Eucalyptus Edema gel group decreased on the 6th day after treatment and the pathological changes were alleviated. The levels of IL-4, IL-17, IL-31 and LTC4 were decreased (P <0.05) And Cys LTR2 protein expression was down-regulated, while there was no significant difference in LTB4 level. CONCLUSION: Eucalyptus euphorbiae gel has a therapeutic effect on eczema in rats, which is related to down-regulation of IL-4, IL-17, IL-31 and LTC4 in serum and expression of Cys LTR1 and Cys LTR2 in skin.